M&A - Haleon plc

Form Type: SCHEDULE 13D/A

Filing Date: 2025-03-20

Corporate Action: Acquisition

Type: Update

Accession Number: 000007800325000074

Filing Summary: On March 20, 2025, Pfizer Inc. filed Amendment No. 14 to the Schedule 13D regarding its beneficial ownership of Haleon plc. As of this date, Pfizer is reported to beneficially own 661,709,764 Ordinary Shares, approximately 7.3% of Haleon plc’s outstanding shares. This amendment is particularly notable due to the planned March 2025 Secondary Offering and the associated March 2025 Share Buyback, under which Pfizer will cease to hold any Ordinary Shares in Haleon once these transactions are executed. The March 2025 Secondary Offering involves an agreement where Pfizer, as the seller, will sell 661,709,764 Ordinary Shares, while the March 2025 Share Buyback will see Haleon repurchase Ordinary Shares from Pfizer totaling an approximate value of GBP170 million, contingent upon the successful closing of the secondary offering. The share price for this transaction is set to be equal to the offering price determined in the secondary offering, estimated at 385 pence per share. The secondary offering is expected to close on March 21, 2025. This summary highlights significant changes in Pfizer’s investment in Haleon plc resulting from these corporate actions.

Document Link: View Document